Drug intelligence / Profile preview

LEAD-452

Development stage: Preclinical
Lead developer: Trimerbody Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LEAD-452 is a humanized bispecific EGFR-targeted 4-1BB-agonistic trimerbody developed by LeadArtis. It is designed to provide enhanced tumor-specific costimulation by simultaneously targeting the epidermal growth factor receptor (EGFR) and activating the 4-1BB (CD137) pathway, which plays a key role in T-cell activation and anti-tumor immune responses. Preclinical studies have demonstrated that LEAD-452 can induce complete cancer regression in mouse models of colon tumors and shows promising safety and efficacy profiles. It is currently in preclinical development for solid tumors including colon cancer, breast cancer, and head and neck neoplasms.

Targets

EGFR (Epidermal growth factor receptor)TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on LEAD-452.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEAD-452.